Evaluation of clinical benefit of metformin tablets combined with drospirenone and ethinylestradiol tablets(Ⅱ)in the treatment of polycystic ovary syndrome
Objective To investigate whether patients with polycystic ovary syndrome(PCOS)can benefit from metformin tablets combined with drospirenone and ethinylestradiol tablets(Ⅱ).Methods A total of 84 PCOS patients diagnosed in Guangzhou Women and Children's Medical Center from January 2021 to December 2022 were selected.According to the treatment plan and homeostasis model assessment of insulin resistance(HOMA-IR)index,patients were divided into monotherapy normal group[drospirenone and ethinylestradiol tablets(Ⅱ),HOMA-IR index<2.69,n=29],monotherapy abnormal group[drospirenone and ethinylestradiol tablets(Ⅱ),HOMA-IR index≥2.69,n=15],combination normal group[drospirenone and ethinylestradiol tablets(Ⅱ)+ metformin,HOMA-IR index<2.69,n=11]and combination abnormal group[drospirenone and ethinylestradiol tablets(Ⅱ)+ metformin,HOMA-IR index≥2.69,n=29].Luteinizing hormone(LH),testosterone(T),sex hormone binding globulin(SHBG),HOMA-IR index and efficacy of all groups were compared.Results Before treatment,HOMA-IR index of patients in monotherapy abnormal group was significantly higher than that in monotherapy normal group(P<0.05),and HOMA-IR index of patients in combination abnormal group was significantly higher than that in combination normal group(P<0.05).After treatment,LH and T of four groups were significantly lower than before treatment,and SHBG was significantly higher than before treatment(P<0.05).The HOMA-IR index of patients in other three groups was significantly lower than before treatment except monotherapy normal group(P<0.05).After treatment,HOMA-IR index of patients with monotherapy abnormal group was significantly higher than that of patients with monotherapy normal group(P<0.05).There were no significant differences in LH,T,HOMA-IR index and SHBG between combination normal group and combination abnormal group(P>0.05).There was no significant difference in total effective rate between monotherapy normal group and combination normal group(χ2=3.398,P=0.183).The total effective rate in combination abnormal group was significantly higher than that in monotherapy abnormal group(χ2=6.360,P=0.042).Conclusion The combination of metformin tablets combined with drospirenone and ethinylestradiol tablets(Ⅱ)can improve insulin resistance in patients,and the combination regimen will benefit more patients with PCOS and insulin resistance.
Drospirenone and ethinylestradiol tablets(Ⅱ)MetforminPolycystic ovary syndromeInsulin resistance
国家科技期刊平台
NSTL
万方数据
维普
